Newsletter | February 19, 2025

02.19.25 -- A Primer On The RNA Patent Landscape

SPONSOR

Join Advancing RNA Live for a deep dive into mRNA-LNP development, tackling key CQAs, manufacturing challenges, and the need for innovation in analytics, PAT, automation, and more. Explore strategies to enhance quality at smaller scales and navigate the future of advanced manufacturing. Reserve your spot for this free digital event happening March 13th!

FEATURED EDITORIAL

A Primer On The RNA Patent Landscape

In the first- of this three-part article, Shores gives us an important primer on the RNA legal landscape as it stands today. As many of us are working on crafting the next generation of mRNA/RNA products and LNPs, I wanted to get his sense of how our continued scientific advancement is likely to impact the IP landscape in the long-term.

How Outsourcing mRNA Development Has Evolved Since COVID

Advancing RNA panelists Alex Aust, Qian Ruan, and Andy Geal share their thoughts on the ways in which outsourcing firms are approaching mRNA development today, as well as why outsourcing — as opposed to building a GMP facility — remains critical for (x)RNA biotechs today.

Biotech Story Time With Tal Zaks, M.D. (Part 2)

Dr. Tal Zaks joins the Business of Biotech for the second part of "Story Time With Tal," discussing his transition from Moderna's CMO during the COVID-19 pandemic to co-founding Exsilio Therapeutics, an mRNA startup. The episode explores Exsilio's foundation, scientific focus, team recruitment, and its $82 million Series A funding.

INDUSTRY INSIGHTS

Developing An mRNA-Encoded Antibody Platform

We present the foundation of an mRNA-LNP platform for encoding and expressing therapeutic antibodies in vivo, eliminating the need for costly and time-consuming manufacturing.

Assessing The Global Clinical Trial Landscape For RNA Therapies

This resource offers a detailed analysis of the global RNA trial landscape, highlighting the growth in trials, especially in the Asia-Pacific region, which has seen a 26% annual growth rate.

How To Value Automation With The Return On Invested Capital Model

Gain insight into the Return on Invested Capital (ROIC) advantages of an automated manufacturing facility and its correlation to the digital maturity of your operation.

Modulate mRNA Therapy Effectiveness Using Modified Ribonucleotides

Learn about the problem of immunogenicity of mRNA, modified mRNA via in vitro transcription production, and choosing fit-for-purpose modified ribonucleotides.

Downstream Processing's Role In Optimizing RNA-LNP Drug Development

Explore the key aspects of lipid nanoparticle (LNP) development, including the essential downstream processes of Tangential Flow Filtration (TFF) and normal flow filtration.

Exploring Progress In Nanomedicine

Gene therapy offers hope for rare genetic diseases, with advancements in polymer nanoparticles addressing delivery challenges and paving the way for innovative, effective treatments.

High-Throughput Lipid Separation For LNP Formulations

Lipid nanoparticles (LNPs) carry immense potential as delivery systems. Learn about the development of isocratic and gradient methods for high-throughput separation of lipids used in LNP formulations.

Optimizing mRNA: A Guide To Enhanced Stability, Delivery, And Efficacy

RNA offers exciting potential for vaccines, gene therapies, and personalized medicine, but challenges related to stability, delivery, and manufacturing persist.